Form 4: Ideaya Biosciences Executive Acquires Stock Options
SEC Form 4 Filing
Darrin Beaupre, Chief Medical Officer of Ideaya Biosciences, acquired stock options for 160,000 shares on March 1, 2024.
Summary
- Darrin Beaupre, the Chief Medical Officer of Ideaya Biosciences, Inc. (IDYA), filed a Form 4 on March 4, 2024, reporting a transaction.
- On March 1, 2024, Beaupre acquired stock options for 160,000 shares of Ideaya's common stock at an exercise price of $46.22.
- The options vest over four years, starting with 25% vesting on January 1, 2025, and the remainder vesting monthly thereafter.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard reporting of stock option grants to an executive.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The acquisition of stock options by a key executive could signal confidence in the company's future performance to shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/01/2024 | Date of stock option acquisition |
| 01/01/2025 | First vesting date for 25% of the shares |
| 02/28/2034 | Expiration date of the stock options |
| 03/04/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.